PD
NMRA icon

Point72 (DIFC)’s Neumora Therapeutics NMRA Stock Holding History

Point72 (DIFC)’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$93 Sell
51
-1,068
-95% -$1.73K ﹤0.01% 1109
2025
Q2 		$821 Buy
+1,119
New +$848 ﹤0.01% 1440

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Point72 (DIFC)'s NMRA Position: Q3 2025 in Review

Point72 (DIFC) reduced its Neumora Therapeutics (NMRA) stake by 95% in Q3 2025, selling an estimated $1.73K and leaving 51 shares worth $93. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

Point72 (DIFC) first reported a position in NMRA in Q2 2025 and has held it in 2 quarters since. The position peaked at $821 in Q2 2025. 93 funds tracked by Wall St. Rank hold NMRA as of Q3 2025.

  • Point72 (DIFC) held 51 shares of Neumora Therapeutics worth $93 as of Q3 2025.
  • Point72 (DIFC) sold 1,068 Neumora Therapeutics shares in Q3 2025, an estimated $1.73K.
  • Neumora Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #1109 holding.
  • Point72 (DIFC) first reported a position in Neumora Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Point72 (DIFC)'s Neumora Therapeutics position peaked at $821 in Q2 2025.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.